Literature DB >> 22309281

Angioedema after intravitreal bevacizumab injection.

Yasin Toklu1, Ozge Sarac, Sule Berk, Saban Simsek.   

Abstract

A 47-year-old male with a history of diabetes mellitus type 2 exhibited with decreased vision in both eyes. The diagnosis of cystoid macular edema (CME) was made and it was decided to administer bilateral intravitreal bevacizumab (Avastin) injections. After intravitreal bevacizumab injection (1.25 mg/0.05 cc) to the right eye the patient had angioedema and conjunctival chemosis in the right eye which resolved in 48 h. One month later the left eye received intravitreal bevacizumab injection under the same conditions. Thirty minutes after the injection angioedema and conjunctival chemosis occurred in the left eye in which the signs and symptoms improved in 48 h. This report is the first one which describes angioedema after intravitreal bevacizumab injection. Care should be taken against the systemic hypersensitivity reactions when planned to receive intravitreal bevacizumab injection.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22309281     DOI: 10.3109/15569527.2011.609207

Source DB:  PubMed          Journal:  Cutan Ocul Toxicol        ISSN: 1556-9527            Impact factor:   1.820


  1 in total

1.  A case of late-onset larynx angioedema after ranibizumab intravitreal injection: Ranibizumab-related angioedema.

Authors:  Maddalena De Bernardo; Cristiana Stellato; Nicola Rosa; Ilaria De Pascale; Francesco Antonio Salzano
Journal:  Int J Immunopathol Pharmacol       Date:  2020 Jan-Dec       Impact factor: 3.219

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.